No Association between the Plasmodium vivax <i>crt-o</i> MS334 or In9 <i>pvcrt</i> Polymorphisms and Chloroquine Failure in a Pre-Elimination Clinical Cohort from Malaysia with a Large Clonal Expansion-Reference-Cited by-同舟云学术

No Association between the Plasmodium vivax crt-o MS334 or In9 pvcrt Polymorphisms and Chloroquine Failure in a Pre-Elimination Clinical Cohort from Malaysia with a Large Clonal Expansion

Published:2023-07-18 Issue:7 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Rumaseb Angela¹,Moraes Barros Roberto R.²,Sá Juliana M.³,Juliano Jonathan J.⁴,William Timothy⁵⁶,Braima Kamil A.¹,Barber Bridget E.¹⁷,Anstey Nicholas M.¹⁶,Price Ric N.¹⁸⁹,Grigg Matthew J.¹⁶,Marfurt Jutta¹¹⁰,Auburn Sarah¹⁸⁹^ORCID

Affiliation:

1. Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia

2. Department of Microbiology, Immunology and Parasitology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil

3. Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

4. Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

5. Clinical Research Centre, Queen Elizabeth Hospital, Sabah, Malaysia

6. Infectious Diseases Society Sabah-Menzies School of Health Research Clinical Research Unit, Kota Kinabalu, Sabah, Malaysia

7. QIMR Berghofer Medical Research Institute, Brisbane, Australia

8. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

9. Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand

10. College of Medicine and Public Health, Flinders University, Darwin, Northern Territory, Australia

Abstract

Increasing reports of resistance to a frontline malaria blood-stage treatment, chloroquine (CQ), raises concerns for the elimination of Plasmodium vivax . The absence of an effective molecular marker of CQ resistance in P. vivax greatly constrains surveillance of this emerging threat.

Funder

DHAC | National Health and Medical Research Council

Malaysian Ministry of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01610-22

Reference35 articles.

1. The changing epidemiology of Plasmodium vivax: Insights from conventional and novel surveillance tools

2. WHO. 2021. World Malaria Report 2021, p. 248–258. World Health Organization, Geneva, Switzerland.

3. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis

4. Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax

5. Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Are pvcrt-o and pvmdr1 Gene Mutations Associated with Plasmodium vivax Chloroquine-Resistant Parasites?;Biomedicines;2024-01-09